Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (LEE011) in Patients With Advanced or Recurrent Endometrial Carcinoma

NCT03008408 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03008408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03008408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (LEE011) in Patients With Advanced or Recurrent Endometrial Carcinoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 18, 2017
Completion date
August 31, 2028
Enrollment
90 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent endometrial carcinoma, recurrent endometrial endometrioid adenocarcinoma, refractory endometrial carcinoma, refractory endometrial endometrioid adenocarcinoma, stage iii uterine corpus cancer ajcc v8, stage iiia uterine corpus cancer ajcc v8, stage iiib uterine corpus cancer ajcc v8, stage iiic uterine corpus cancer ajcc v8, stage iiic1 uterine corpus cancer ajcc v8, stage iiic2 uterine corpus cancer ajcc v8, stage iv uterine corpus cancer ajcc v8, stage iva uterine corpus cancer ajcc v8, stage ivb uterine corpus cancer ajcc v8